Oncopeptides develops the candidate drug melflufen to improve the treatment of multiple myeloma, an incurable form of blood cancer that affects more than 100,000 people in the West each year. Melflufen has a unique mode of action and is demonstrating a high clinical anti-cancer effect and favorable side effect profile in an ongoing trial. Clinical development activities are ongoing to show its efficacy in comparison with existing treatment options. Melflufen has potential to improve the medical treatment of these extremely ill patients.
Melflufen has been granted orphan drug status in both the US and Europe. Preparations for pivotal trials in multiple myeloma are currently ongoing. Oncopeptides also intends to initiate phase I/II trials for additional cancer indications.
Oncopeptides at a glance
What they do: Preparing pivotal programs for the candidate drug melflufen – a new targeted treatment of multiple myeloma
Founded in: 2000
Headquarters: Stockholm, Sweden